SAMN03290919
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.400
- COAGULATION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- KRAS_SIGNALING_DN+0.400
- APICAL_JUNCTION+0.300
- HYPOXIA+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- MYOGENESIS+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.600
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- MITOTIC_SPINDLE-0.400
- MYC_TARGETS_V2-0.400
- ANDROGEN_RESPONSE-0.300
- UV_RESPONSE_DN-0.300
- HEDGEHOG_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290907 | — | — | 0.942 |
| 2 | SAMN03290904 | — | — | 0.927 |
| 3 | SAMN03290902 | — | — | 0.925 |
| 4 | SAMN03290893 | — | — | 0.925 |
| 5 | SJEPD035_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.862 |
| 6 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.852 |
| 7 | fb24d93c-9681-4d45-801f-9dcfd8c5703e | — | — | 0.842 |
| 8 | SAMN03290921 | — | — | 0.842 |
| 9 | SAMN03290901 | — | — | 0.842 |
| 10 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |